Document:

exv10w15

 

Exhibit 10.15

ASSIGNMENT

AND

GRANT-BACK OF LICENSE

     This Agreement is effective November 28, 2001 by and between Pi Medical, Inc., 2800 Patton
Road, St. Paul, MN 55113 (“Pi Medical”) and Venturi Development Inc., 2800 Patton Road, St. Paul,
MN 55113 (“VDI”) (Pi Medical and VDI are collectively referred to as the “Parties”).

     For one dollar and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties agree as follows:

	1.	 	Pi Medical hereby irrevocably assigns to VDI its entire right, title and
interest to all copyrights, patents, if any, inventions and supporting documentation
and software in all of the standard operating procedures, policies and systems
identified in the attached Exhibit A.
	 
	2.	 	VDI hereby grants back to Pi Medical a non-exclusively, worldwide, fully paidup
license to all rights assigned in the above Section 1.

	 	 	 	 	 	 	 
	Agreed to by:	 	 	 	 
	 
	 	 	 	 	 	 
	Pi Medical, Inc.	 	Venturi Development, Inc.
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Timothy R. Conrad
	 	By:
	 	/s/ Mark. B. Knudson
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Printed Name: Timothy R. Conrad	 	Printed Name: Mark B. Knudson
	 
	 	 	 	 	 	 
	Its: Vice President	 	Its: President
	 
	 	 	 	 	 	 
	Date: November 28, 2001	 	Date: November 28, 2001

 

 

EXHIBIT “A”

	 	 	 	 	 	 	 
	Document	 	 	 	Effective	 	 
	Number	 	Description	 	Date	 	Rev. Level
	POLICY-01
	 	Quality Manual Policy	 	2/28/2002	 	C
	POLICY-02
	 	Information Security File	 	Pending	 	—
	POLICY-03
	 	Safety policy	 	Pending	 	—
	SOP1001
	 	Product Design and Development Procedure	 	12/7/2001	 	F
	SOP1002
	 	Test Management Procedure	 	1/11/2002	 	E
	SOP1003
	 	Test Protocol / Reporting Procedure	 	8/1/2001	 	D
	SOP1004
	 	Risk Analysis Procedure	 	12/17/2001	 	B
	SOP1005
	 	Verification, Validation and Qualification Testing Requirements	 	11/19/2001	 	C
	SOP1006
	 	Laboratory Notebook & Invention Disclosure Procedure	 	1/16/2002	 	C
	SOP1007
	 	Use	 	—	 	—
	SOP1008
	 	Pre-Clinical Studies	 	8/1/2001	 	C
	SOP1010
	 	Software Development and Validation Manufacturing/Test Software	 	5/16/2001	 	A
	SOP1011
	 	Product Biocompatibility	 	12/14/2001	 	B
	SOP3001
	 	Document Generation, Content, and Identification	 	1/16/2002	 	F
	SOP3002
	 	Change Order	 	1/16/2002	 	E
	SOP3003
	 	Document and Data Storage and Access	 	1/8/2002	 	B
	SOP3004
	 	Article Identification:  Definition, Description, and Administration	 	12/11/2001	 	C
	SOP3005
	 	Review, Approval, and Control of Labeling and Literature	 	10/25/2001	 	B
	SOP3006
	 	Use	 	—	 	—
	SOP3007
	 	Technical File procedure	 	3/4/2002	 	A
	SOP3008
	 	Standards Library/Database Procedure	 	9/11/2001	 	A
	SOP3009
	 	Document Formatting Standards	 	12/11/2001	 	B
	SOP4001
	 	Supplier Selection, Qualification and Certification Procedure	 	1/18/2002	 	D
	SOP4002
	 	Supplier Auditing Procedure	 	1/18/2002	 	D
	SOP4003
	 	Request for Quote/Request for Information Process	 	7/10/2001	 	B
	SOP4004
	 	Purchase Order Procedure	 	12/11/2001	 	E
	SOP4005
	 	Purchase Requisition and Amendment	 	3/11/2002	 	C
	SOP4006
	 	Device History Records	 	9/25/2001	 	C
	SOP4007
	 	Non-Conforming Material Review Board	 	9/25/2001	 	B
	SOP4008
	 	Product Receiving, Handling, and Storage	 	6/15/2001	 	B
	SOP4009
	 	Material Identification and Acceptance Status Procedure	 	2/1/2002	 	D
	SOP4010
	 	Lot/Serial Number Control	 	8/22/2001	 	B
	SOP5001
	 	Product Monographs	 	2/1/2002	 	F
	SOP5002
	 	Manufacturing Procedure Content	 	5/7/2002	 	B
	SOP5003
	 	Preventive Maintenance System	 	9/20/2001	 	B

A-1

 

	 	 	 	 	 	 	 
	Document	 	 	 	Effective	 	 
	Number	 	Description	 	Date	 	Rev. Level
	SOP5004
	 	Custom Tool Approval	 	1/18/2002	 	B
	SOP5005
	 	Custom Equipment Selection, Acceptance and Qualification	 	1/9/2002	 	B
	SOP5006
	 	Product Sterilization, Ethylene Oxide Procedure	 	1/21/2002	 	C
	SOP5007
	 	Process Control	 	10/22/2001	 	A
	SOP5008
	 	Statistical Techniques	 	4/11/2001	 	A
	SOP5009
	 	Controlled Environment	 	4/26/2002	 	E
	SOP5010
	 	Product Inspection Test, and Acceptance	 	2/26/2002	 	B
	SOP5011
	 	Engineering Evaluations	 	2/26/2002	 	B
	SOP5012
	 	Product Sterilization, Radiation Procedure	 	4/16/2002	 	A
	SOP6001
	 	Non-Disclosure Agreement	 	1/18/2002	 	B
	SOP6002
	 	Consulting Agreements Procedure	 	1/18/2002	 	C
	SOP6003
	 	Employee Training Program	 	1/21/2002	 	B
	SOP6004
	 	Employee Position Descriptions	 	2/25/2002	 	C
	SOP6005
	 	Employee Performance Evaluation	 	1/21/2002	 	B
	SOP6006
	 	Training Database	 	1/21/2002	 	B
	SOP6007
	 	Facility Controls	 	6/25/2001	 	A
	SOP6008
	 	Signature Authority and Delegation of Signature Authority	 	1/22/2002	 	B
	SOP6009
	 	Disaster and Evacuation Protocol	 	3/27/2002	 	B
	SOP6010
	 	Accounts Payable - Invoice Approval Process	 	6/25/2001	 	A
	SOP6011
	 	Property Identification Tracking System	 	10/3/2001	 	B
	SOP6012
	 	Chemical Ordering	 	Pending	 	—
	SOP6013
	 	Hazardous Waste Management	 	Pending	 	—
	SOP6014
	 	Hazard Communication Program (Right to Know)	 	Pending	 	—
	SOP6015
	 	Bloodborne Pathogen Procedure	 	Pending	 	—
	SOP7001
	 	Clinical Trial Overview	 	5/8/2002	 	A
	SOP7002
	 	Use	 	—	 	—
	SOP7003
	 	Writing A Clinical Protocol	 	2/27/2002	 	D
	SOP7004
	 	Writing An Investigators Brochure	 	2/27/2002	 	B
	SOP7005
	 	Site Initiation	 	2/27/2002	 	B
	SOP7006
	 	Routine Monitoring Visits	 	2/27/2002	 	B
	SOP7007
	 	Study Close-out Visits	 	6/6/2001	 	A
	SOP7008
	 	CRF Processing and Data Management	 	10/18/2001	 	B
	SOP7009
	 	Study Final report	 	5/8/2002	 	A
	SOP7010
	 	Clinical Study Files	 	5/8/2002	 	 
	SOP7011
	 	Product Recalls/Field Corrective Actions	 	9/27/2001	 	A
	SOP7012
	 	Management Review Procedure	 	8/27/2001	 	B
	SOP7013
	 	Medical Device Reporting	 	3/1/2002	 	B
	SOP7014
	 	Internal deviations	 	Pending	 	—

A-2

 

	 	 	 	 	 	 	 
	Document	 	 	 	Effective	 	 
	Number	 	Description	 	Date	 	Rev. Level
	SOP7015
	 	Gage Repeatability and Reproducibility Evaluations	 	2/15/2002	 	B
	SOP7016
	 	Calibration System Procedure	 	3/5/2002	 	C
	SOP7017
	 	Adverse Event Reportind	 	4/9/2001	 	A
	SOP7018
	 	Vigilance Reporting	 	9/27/2001	 	A
	SOP7019
	 	Biohazard Material Handling	 	Pending	 	—
	SOP7020
	 	Internal Quality Audits	 	11/5/2001	 	C
	SOP7021
	 	Complaint and Return Goods Analysis	 	3/1/2002	 	B
	SOP7022
	 	Corrective and Preventive Actions (CAPA)	 	8/27/2001	 	B
	SOP7023
	 	Regulatory Inspections	 	3/1/2002	 	B
	SS-001
	 	ASD I, System Specification	 	9/21/2001	 	B
	SS-002
	 	CAPA Database, System Specification	 	6/25/2001	 	B
	SS-003
	 	Delivery System II, System Specification	 	12/18/2001	 	B
	SS-004
	 	Test Log	 	6/6/2001	 	A
	SS-005
	 	Preventive Maintenance Database, System Specification	 	7/31/2001	 	A
	SS-006
	 	Suppliers and Associated Lot Information Database (ASL)	 	4/22/2002	 	B

A-3exv10w11

 

EXHIBIT 10.11 

UNIT PLACEMENT AGREEMENT

     UNIT PLACEMENT AGREEMENT (this “Agreement”) made as of this ___day of March 2006 among JK
Acquisition Corp., a Delaware corporation (the “Company”), Ferris, Baker Watts Incorporated (“FBW”)
and the undersigned (the “Purchasers”).

     WHEREAS, the Company has filed with the Securities and Exchange Commission (“SEC”) a
registration statement on Form S-1, as amended (File No. 333-125211) (the “Registration
Statement”), in connection with the Company’s initial public offering (the “IPO”) of up to
9,666,666 units, each unit (“Unit”) consisting of one share of the Company’s common stock, $.0001
par value (the “Common Stock”), and (ii) two warrants (the “Warrants”), each Warrant to purchase
one share of Common Stock; and

     WHEREAS, the Company desires to sell in a private placement to the Purchasers (the
“Placement”) an aggregate of 333,334 units (the “Placement Units”) substantially identical to the
Units being issued in the IPO pursuant to the terms and conditions hereof and as set forth in the
Registration Statement, except that the Placement Units, Common Stock and Warrants to be issued in
the Placement shall not be registered under the Securities Act of 1933, as amended (the “Securities
Act”);

     WHEREAS, each Purchaser desires to acquire the number of Placement Units set forth opposite
his name on Schedule A hereto;

     WHEREAS, the Warrants included in the Placement Units shall be governed by the Warrant
Agreement filed as an exhibit to the Registration Statement; and

     WHEREAS, the Purchasers are entitled to registration rights with respect to the Common Stock
and the Warrants comprising the Placement Units and the Common Stock underlying such Warrants
(collectively, the “Registrable Securities”) on the terms set forth in this Agreement; and

     WHEREAS, FBW is acting as placement agent for the Placement.

     NOW, THEREFORE, for and in consideration of the premises and the mutual covenants hereinafter
set forth, the parties hereto do hereby agree as follows:

	 	1.	 	Purchase of Units. The Purchasers hereby agree, directly or through nominees, to
purchase an aggregate of 333,334 Placement Units at a purchase price of $6.00 per Placement
Unit, or an aggregate of $2,000,004 (the “Purchase Price”). Such purchases shall be in the
names and amounts set forth on Schedule A hereto.
	 
	 	2.	 	Closing. The closing of the purchase and sale of the Placement Units (the “Closing”)
will take place at such time and place as the parties may agree (the “Closing Date”), but
in no event later than the date on which the SEC declares the Registration Statement
effective (the “Effective Date”). On the Effective Date, the Purchasers shall pay the
Purchase Price

 

 

	 	 	 	by wire transfer of funds to an account maintained by the Company. Immediately prior to the
closing of the IPO, the Company shall deposit $2,000,004 of the Purchase Price into the
trust account described in the Registration Statement (the “Trust Account”). The
certificates for the Common Stock and Warrants comprising the Placement Units shall be
delivered to the Purchasers promptly after the closing of the IPO.
	 
	 	3.	 	Voting of Shares. If the Company solicits approval of its stockholders of a Business
Combination, the Purchasers shall vote all of the shares of the Common Stock acquired by
the Purchasers (i) pursuant to this Agreement, (ii) in the IPO and (iii) in the aftermarket
in favor of the Business Combination and therefore waive any redemption rights they might
have with respect to certain of such shares. As used herein, a “Business Combination” shall
mean an acquisition by merger, capital stock exchange, asset or stock acquisition of, or
similar business combination with, one or more entities with agreements to acquire vessels
or an operating business in the shipping industry selected by the Company.
	 
	 	4.	 	Waiver of Liquidation Distributions. In connection with the Placement Units purchased
pursuant to this Agreement, the Purchasers hereby waive any and all right, title, interest
or claim of any kind in or to any liquidating distributions by the Company in the event of
a liquidation of the Company upon the Company’s failure to timely complete a Business
Combination. For purposes of clarity, any shares of Common Stock purchased in the IPO or
the aftermarket by the Purchasers shall be eligible to receive any liquidating
distributions by the Company.
	 
	 	5.	 	Lock-Up Agreement. The Purchasers shall not sell, assign, hypothecate, or transfer any
of the Common Stock purchased pursuant to this Agreement until the earlier of consummation
of a Business Combination or liquidation of the Company. In order to enforce this covenant,
the undersigned agrees, if requested by FBW, to deposit the Placement Units in an account
to be established at FBW.
	 
	 	6.	 	Representations and Warranties of the Purchasers. Each Purchaser hereby represents and
warrants to the Company that:

	 	6.1	 	The Purchaser is an “accredited investor” as that term is defined in Rule 501
of Regulation D promulgated under the Securities Act.
	 
	 	6.2	 	The Placement Units, Common Stock and Warrants are being acquired for the
Purchaser’s own account, only for investment purposes and not with a view to, or for
resale in connection with, any distribution or public offering thereof within the
meaning of the Securities Act.
	 
	 	6.3	 	The Purchaser has the full right, power and authority to enter into this
Agreement and this Agreement is a valid and legally binding obligation of the Purchaser
enforceable against the Purchaser in accordance with its terms.

 

 

	 	7.	 	Registration Rights.

	 	7.1	 	Demand Registration. At any time and from time to time on or after the date on
which the Company has publicly announced that it has entered into a letter of intent or
made a comparable announcement with respect to a Business Combination, the Purchasers
or their transferees holding a majority-in-interest of the Registrable Securities may
make a written demand for registration under the Securities Act of all or part of their
Registrable Securities (a “Demand Registration”). Any demand for a Demand Registration
shall specify the number of Registrable Securities proposed to be sold and the intended
method(s) of distribution thereof. The Company will notify all holders of Registrable
Securities of the demand, and each holder of Registrable Securities who wishes to
include all or a portion of such holder’s Registrable Securities in the Demand
Registration (each such holder including shares of Registrable Securities in such
registration, a “Demanding Holder”) shall so notify the Company within fifteen (15)
days after the receipt by the holder of the notice from the Company. Upon any such
request, the Demanding Holders shall be entitled to have their Registrable Securities
included in the Demand Registration.
	 
	 	 	 	The Company shall, as expeditiously as possible and in any event within sixty (60) days
after receipt of a request for a Demand, prepare and file with the SEC a Registration
Statement on any form for which the Company then qualifies or which counsel for the
Company shall deem appropriate and which form shall be available for the sale of all
Registrable Securities to be registered thereunder in accordance with the intended
method(s) of distribution thereof, and shall use its best efforts to cause such
Registration Statement to become effective as promptly as practicable, but in no event
prior to the consummation of the Business Combination.
	 
	 	 	 	The Company shall not be obligated to effect more than two Demand Registrations in
respect of Registrable Securities.
	 
	 	7.2	 	“Piggyback” Registration Rights. Subject to the last sentence of this Section
7.2, at any time after a Business Combination, if the Company shall determine to
proceed with the actual preparation and filing of a new registration statement under
the Securities Act in connection with the proposed offer and sale of any of its
securities by it or any of its security holders (other than a registration statement on
Form S-4, S-8 or other limited purpose form), the Company will give written notice of
its determination to the Purchasers or their nominees. Upon the written request from a
majority-in-interest of the Purchasers, within 15 days after receipt of any such notice
from the Company, the Company will, except as herein provided, cause all of the
Registrable Securities covered by such request (the “Requested Stock”) held by the
Purchasers making such request (the “Requesting Holders”) to be included in such
registration statement (each, a “Piggy-Back Registration”), all to the extent requisite
to permit the sale or other disposition by the prospective seller or sellers of the
Requested Stock; provided, further, that nothing herein shall prevent the Company from,
at any time, abandoning or delaying any registration. If any registration pursuant to
this Section 7.2 shall be underwritten in whole or in part, the Company

 

 

	 	 	 	may require that the Requested Stock be included in the underwriting on the same terms
and conditions as the securities otherwise being sold through the underwriters. In such
event, the Requesting Holders shall, if requested by the underwriters, execute an
underwriting agreement containing customary representations and warranties by selling
stockholders and a lock-up on Registrable Securities not being sold. If in the good
faith judgment of the managing underwriter of such public offering the inclusion of all
of the Requested Stock would reduce the number of shares to be offered by the Company or
interfere with the successful marketing of the shares of stock offered by the Company,
the number of shares of Requested Stock otherwise to be included in the underwritten
public offering may be reduced pro rata (by number of shares) among the Requesting
Holders and all other holders of registration rights who have requested inclusion of
their securities or excluded in their entirety if so required by the underwriter. To the
extent only a portion of the Requested Stock is included in the underwritten public
offering, those shares of Requested Stock which are thus excluded from the underwritten
public offering and any other securities of the Company held by such holders shall be
withheld from the market by the Holders thereof for a period, not to exceed 90 days,
which the managing underwriter reasonably determines is necessary in order to effect the
underwritten public offering. At such time as the provisions of the registration rights
agreement filed as an exhibit to the Registration Statement covering the shares of
Common Stock acquired by the Purchasers prior to the IPO may be exercised, the exercise
and procedural provisions of such agreement, rather than the provisions of Sections 7.2,
7.3 and 7.4 hereof, shall govern the Registrable Securities with respect to Piggy-Back
Registrations.
	 
	 	7.3	 	Registration Procedures. To the extent required by Sections 7.1 or 7.2, the
Company will:

	 	(a)	 	prepare and file with the SEC a registration statement with respect to
such securities, and use its best efforts to cause such registration statement to
become and remain effective until the earlier of the date on which all of the
Registrable Securities included in the registration statement have been disposed of
in accordance with the intended method(s) of distribution set forth in such
Registration Statement or three years from the effective date;
	 
	 	(b)	 	prepare and file with the SEC such amendments to such registration
statement and supplements to the prospectus contained therein as may be necessary
to keep such registration statement effective until the earlier of the date on
which all of the Registrable Securities included in the registration statement have
been disposed of in accordance with the intended method(s) of distribution set
forth in such Registration Statement or three years from the effective date;
	 
	 	(c)	 	furnish to the holders participating in such registration and to the
underwriters of the securities being registered such reasonable number of copies of
the registration statement, preliminary prospectus, final prospectus and such other
documents as such underwriters may reasonably request in order to facilitate the
public offering of such securities;
	 
	 	(d)	 	use its best efforts to register or qualify the securities covered by
such registration statement under such state securities or blue sky laws of such
jurisdictions as the

 

 

	 	 	 	holders may reasonably request in writing within 20 days following the original
filing of such registration statement, except that the Company shall not for any
purpose be required to execute a general consent to service of process or to qualify
to do business as a foreign corporation in any jurisdiction wherein it is not so
qualified;
	 
	 	(e)	 	notify the holders, promptly after it shall receive notice thereof, of
the time when such registration statement has become effective or a supplement to
any prospectus forming a part of such registration statement has been filed;
	 
	 	(f)	 	notify the holders promptly of any request by the SEC for the amending
or supplementing of such registration statement or prospectus or for additional
information;
	 
	 	(g)	 	prepare and promptly file with the SEC and promptly notify such holders
of the filing of such amendment or supplement to such registration statement or
prospectus as may be necessary to correct any statements or omissions if, at the
time when a prospectus relating to such securities is required to be delivered
under the Securities Act, any event shall have occurred as the result of which any
such prospectus or any other prospectus as then in effect would include an untrue
statement of a material fact or omit to state any material fact necessary to make
the statements therein, in the light of the circumstances in which they were made,
not misleading; and
	 
	 	(h)	 	advise the holders, promptly after it shall receive notice or obtain
knowledge thereof, of the issuance of any stop order by the SEC suspending the
effectiveness of such registration statement or the initiation or threatening of
any proceeding for that purpose and promptly use its best efforts to prevent the
issuance of any stop order or to obtain its withdrawal if such stop order should be
issued.

The Purchasers shall cooperate with the Company in providing the information necessary to effect
the registration of the Registrable Securities, including completion of customary questionnaires.

	 	7.4	 	Expenses. The Company shall bear all costs and expenses incurred in connection
with any Demand Registration pursuant to Section 7.1, any Piggy-Back Registration
pursuant to Section 7.2, and all expenses incurred in performing or complying with its
other obligations under this Agreement, whether or not the Registration Statement
becomes effective, including, without limitation: (i) all registration and filing fees;
(ii) fees and expenses of compliance with securities or “blue sky” laws (including fees
and disbursements of counsel in connection with blue sky qualifications of the
Registrable Securities); (iii) printing expenses; (iv) the Company’s internal expenses
(including, without limitation, all salaries and expenses of its officers and
employees); (v) the fees and expenses incurred in connection with the exchange listing
of the Registrable Securities; (vi) National Association of Securities Dealers, Inc.
fees; (vii) fees and disbursements of counsel for the Company and fees and expenses for
independent certified public accountants retained by the Company (including the
expenses or costs associated with the delivery of any opinions or comfort letters);
(viii) the fees and expenses of any special experts retained by the Company in
connection with such registration and (ix) the fees and expenses of one

 

 

	 	 	 	legal counsel selected by the holders of a majority-in-interest of the Registrable
Securities included in such registration. The Company shall have no obligation to pay
any underwriting discounts or selling commissions attributable to the Registrable
Securities being sold by the holders thereof, which underwriting discounts or selling
commissions shall be borne by such holders. Additionally, in an underwritten offering,
all selling shareholders and the Company shall bear the expenses of the underwriter pro
rata in proportion to the respective amount of shares each is selling in such offering.

	 	8.	 	Waiver of Claims; Indemnification The Purchasers hereby waive any and all rights to
assert any present or future claims, including any right of rescission, against the
Company, FBW or the other underwriters in the IPO with respect to their purchase of the
Placement Units, and each Purchaser agrees jointly and severally to indemnify and hold the
Company, FBW and the other underwriters in the IPO harmless from all losses, damages or
expenses that relate to claims or proceedings brought against the Company, FBW or such
other underwriters by any Purchaser of the Placement Units or their transferees, heirs,
assigns or any subsequent holders of the Placement Units.
	 
	 	9.	 	Counterparts; Facsimile. This Agreement may be executed in any number of counterparts,
each of which when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same instrument. This Agreement or any counterpart
may be executed via facsimile transmission, and any such executed facsimile copy shall be
treated as an original.
	 
	 	10.	 	Governing Law. This Agreement shall for all purposes be deemed to be made under and
shall be construed in accordance with the laws of the State of Texas. Each of the
parties hereby agrees that any action, proceeding or claim against it arising out of or
relating in any way to this Agreement shall be brought and enforced in the courts of the
State of Texas or the United States District Court for the District of Texas, and
irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of
the parties hereby waives any objection to such exclusive jurisdiction and that such courts
represent an inconvenient forum.

[Remainder of this page intentionally left blank; signature page follows.]

 

 

     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the ___day of March
2006.

	 	 	 	 	 
	 	 	JK ACQUISITION CORP.
	 
	 	 	 	 
	 

	 	By:
	 	 
	 

	 	 	 	 
	 

	 	Name:
	 	James P. Wilson
	 

	 	 	 	 
	 

	 	Title:
	 	Chairman and Chief Executive Officer
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	FERRIS, BAKER WATTS INCORPORATED
	 
	 	 	 	 
	 

	 	By:
	 	 
	 

	 	 	 	 
	 

	 	Name:
	 	 
	 

	 	 	 	 
	 

	 	Title:
	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	PURCHASERS:
	 
	 	 	 	 
	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 
	 	 	 	 
	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 

 

 

SCHEDULE A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]